HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance

Epigenetics

Volumn 7, Issue 12, 2012, Pages 1403-1412

  Van Damme, Michaël ^a   Crompot, Emerence ^a   Meuleman, Nathalie ^a   Mineur, Philippe ^b   Bron, Dominique ^a   Lagneaux, Laurence ^a   Stamatopoulos, Basile ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b Service des urgences Grand Hôpital de Charleroi   (Belgium)

Author keywords

Chronic lymphocytic leukemia; HDAC; Prognosis; Real time PCR; Sirtuin

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; ISOENZYME; SIRTUIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; ENZYME INDUCTION; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84870750886     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.22674     Document Type: Article

References (43)

1. Workman JL, Kingston RE. Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 1998; 67:545-79; PMID:9759497; http://dx.doi.org/10.1146/annurev.biochem.67.1.545
2. Forsberg EC, Bresnick EH. Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world. Bioessays 2001; 23:820-30; PMID:11536294; http://dx.doi.org/10.1002/ bies.1117
3. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51; PMID:16397526; http://dx.doi.org/10.1038/nrc1779
4. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett 2009; 277:8-21; PMID:18824292; http://dx.doi. org/10.1016/j.canlet.2008.08.016
5. Secrist JP, Zhou X, Richon VM. HDAC inhibitors for the treatment of cancer. Curr Opin Investig Drugs 2003; 4:1422-7; PMID:14763127
6. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009; 280:168-76; PMID:19103471; http://dx.doi.org/10.1016/j. canlet.2008.10.047
7. Hamblin T. Chronic lymphocytic leukaemia: one disease or two? Ann Hematol 2002; 81:299-303; PMID:12107557; http://dx.doi.org/10.1007/s00277-002-0476-1
8. Van Bockstaele F, Verhasselt B, Philippé J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 2009; 23:25-47; PMID:18599169; http://dx.doi.org/10.1016/j. blre.2008.05.003
9. Stamatopoulos B, Meuleman N, De Bruyn C, Mineur P, Martiat P, Bron D, et al. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia 2009; 23:2281-9; PMID:19710697; http://dx.doi. org/10.1038/leu.2009.176
10. Stamatopoulos B, Meuleman N, De Bruyn C, Delforge A, Bron D, Lagneaux L. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. Haematologica 2010; 95:1136-43; PMID:20145270; http://dx.doi.org/10.3324/haematol.2009.013847
11. Stimson L, Wood V, Khan O, Fotheringham S, La Thangue NB. HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 2009; 20:1293-302; PMID:19515748; http://dx.doi. org/10.1093/annonc/mdn792
12. Caligaris-Cappio F, Ghia P. The normal counterpart to the chronic lymphocytic leukemia B cell. Best Pract Res Clin Haematol 2007; 20:385-97; PMID:17707828; http://dx.doi.org/10.1016/j.beha.2007.02.005
13. Farren TW, Giustiniani J, Liu FT, Tsitsikas DA, Macey MG, Cavenagh JD, et al. Differential and tumorspecific expression of CD160 in B-cell malignancies. Blood 2011; 118:2174-83; PMID:21715317; http:// dx.doi.org/10.1182/blood-2011-02-334326
14. Gutierrez AJ Jr., Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, Huddleston PM, et al. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood 2010; 116:2975-83; PMID:20595513; http://dx.doi.org/10.1182/blood-2010-02-269878
15. Gary-Gouy H, Sainz-Perez A, Marteau JB, Marfaing-Koka A, Delic J, Merle-Beral H, et al. Natural phosphorylation of CD5 in chronic lymphocytic leukemia B cells and analysis of CD5-regulated genes in a B cell line suggest a role for CD5 in malignant phenotype. J Immunol 2007; 179:4335-44; PMID:17878328
16. Saunders FK, Lawry J, Winfield DA, Goepel JR, Hancock BW, Sharrard RM, et al. Comparison of protein synthesis profiles in chronic lymphocytic leukaemia cells and B-lymphocytes from peripheral blood, cord blood and tonsil. Experientia 1994; 50:493-6; PMID:7515011; http://dx.doi.org/10.1007/ BF01920755
17. Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004; 10:6962-8; PMID:15501975; http://dx.doi. org/10.1158/1078-0432.CCR-04-0455
18. Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD, et al. Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer 2006; 95:1056-61; PMID:17003781; http://dx.doi. org/10.1038/sj.bjc.6603384
19. Sakuma T, Uzawa K, Onda T, Shiiba M, Yokoe H, Shibahara T, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 2006; 29:117-24; PMID:16773191
20. Ouaïssi M, Sielezneff I, Silvestre R, Sastre B, Bernard JP, Lafontaine JS, et al. High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol 2008; 15:2318-28; PMID:18506539; http://dx.doi. org/10.1245/s10434-008-9940-z
21. Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, et al. Increased gene expression of histone deacetylases in patients with Philadelphianegative chronic myeloproliferative neoplasms. Leuk Lymphoma 2012; 53:123-9; PMID:21806350; http:// dx.doi.org/10.3109/10428194.2011.597905
22. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005; 19:1751-9; PMID:16121216; http://dx.doi.org/10.1038/ sj.leu.2403910
23. Wang JC, Kafeel MI, Avezbakiyev B, Chen C, Sun Y, Rathnasabapathy C, et al. Histone deacetylase in chronic lymphocytic leukemia. Oncology 2011; 81:325-9; PMID:22237050; http://dx.doi. org/10.1159/000334577
24. Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008; 53:267-77; PMID:18671804; http://dx.doi.org/10.1111/j.1365-2559.2008.03109.x
25. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 2004; 112:26-32; PMID:15305372; http://dx.doi.org/10.1002/ ijc.20395
26. Jung KH, Noh JH, Kim JD, Eun JW, Bae JH, Chang Y, et al. HDAC6 functions as a tumor suppressor by activating JNK-mediated beclin 1-dependent autophagic cell death in liver cancer. Hepatology 2012; 56:644-57; PMID:22392728; http://dx.doi.org/10.1002/ hep.25699
27. Bosch-Presegué L, Vaquero A. The dual role of sirtuins in cancer. Genes Cancer 2011; 2:648-62; PMID:21941620; http://dx.doi. org/10.1177/1947601911417862
28. Van Meter M, Mao Z, Gorbunova V, Seluanov A. SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle 2011; 10:3153-8; PMID:21900744; http://dx.doi. org/10.4161/cc.10.18.17435
29. Peters CJ, Rees JRE, Hardwick RH, Hardwick JS, Vowler SL, Ong CA, et al.; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 2010; 139:1995-2004, e15; PMID:20621683; http:// dx.doi.org/10.1053/j.gastro.2010.05.080
30. Inoue T, Hiratsuka M, Osaki M, Oshimura M. The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle 2007; 6:1011-8; PMID:17457050; http://dx.doi.org/10.4161/ cc.6.9.4219
31. Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 2011; 20:487-99; PMID:22014574; http://dx.doi.org/10.1016/j. ccr.2011.09.004
32. Park SH, Ozden O, Jiang H, Cha YI, Pennington JD, Aykin-Burns N, et al. Sirt3, Mitochondrial ROS, Ageing, and Carcinogenesis. Int J Mol Sci 2011; 12:6226-39; PMID:22016654; http://dx.doi. org/10.3390/ijms12096226
33. Lucio-Eterovic AKB, Cortez MAA, Valera ET, Motta FJN, Queiroz RGP, Machado HR, et al. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 2008; 8:243; PMID:18713462; http://dx.doi. org/10.1186/1471-2407-8-243
34. Zhu C, Chen Q, Xie Z, Ai J, Tong L, Ding J, et al. The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc. J Mol Med (Berl) 2011; 89:279-89; PMID:21120446; http://dx.doi. org/10.1007/s00109-010-0701-7
35. Park JH, Kim SH, Choi MC, Lee J, Oh DY, Im SA, et al. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem Biophys Res Commun 2008; 368:318-22; PMID:18211808; http://dx.doi.org/10.1016/j. bbrc.2008.01.056
36. Castro JE, Prada CE, Loria O, Kamal A, Chen L, Burrows FJ, et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 2005; 106:2506-12; PMID:15972449; http://dx.doi. org/10.1182/blood-2005-03-1099
37. Höfling H, Tibshirani R. A study of pre-validation. Ann Appl Stat 2008; 2:643-64; http://dx.doi. org/10.1214/07-AOAS152
38. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1:19-25; PMID:19383284; http://dx.doi.org/10.1016/j. molonc.2007.01.001
39. Stamatopoulos B, Meuleman N, Haibe-Kains B, Duvillier H, Massy M, Martiat P, et al. Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. Clin Chem 2007; 53:1757-66; PMID:17702857; http://dx.doi.org/10.1373/clinchem.2007.089326
40. Stamatopoulos B, Meuleman N, De Bruyn C, Pieters K, Anthoine G, Mineur P, et al. A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients. PLoS One 2010; 5:5; PMID:20862275; http://dx.doi. org/10.1371/journal.pone.0012780
41. Montserrat E, Sanchez-Bisono J, Viñolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62:567-75; PMID:3954968; http:// dx.doi.org/10.1111/j.1365-2141.1986.tb02969.x
42. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910-6; PMID:11136261; http:// dx.doi.org/10.1056/NEJM200012283432602
43. Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, et al. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009; 113:5237-45; PMID:19144983; http://dx.doi. org/10.1182/blood-2008-11-189407